Noticing bleeding while using hormone treatment can raise two immediate questions: is it related to the medicines, and does it need attention? The first cannot be answered reliably from timing alone. For bleeding after menopause, the second should lead to contact with a clinician rather than reassurance from a product page.
This guide helps you prepare an accurate account and understand the difference between reviewing a hormone plan and evaluating a symptom. It does not diagnose the cause, decide which investigation you need or provide instructions for changing estrogen or progesterone. New bleeding deserves a clinical response even when the prescription itself is familiar.
Start with the symptom rather than an explanation for it
Report spotting as well as more obvious bleeding. Tell the clinician whether this is a new event, a change from a previously discussed pattern or bleeding after a period without it. ACOG's menopause-bleeding guidance says that bleeding after menopause should be evaluated; many possible explanations exist, including conditions that require treatment.
Being on hormone therapy does not establish that the medicines caused the bleeding or make the episode automatically acceptable. Neither does it establish cancer. Those are conclusions that require assessment. If bleeding is heavy and accompanied by faintness, chest pain or shortness of breath, seek urgent medical care rather than waiting for a routine portal response. ACOG's abnormal-bleeding guidance addresses emergency symptoms alongside heavy bleeding.
Give enough detail to help the team decide the next step
Record when the bleeding began, whether it stopped, whether it followed sex and whether there was pain or another new symptom. Describe the amount in ordinary terms and say if it is difficult to estimate. If you are uncertain whether blood came from the vagina, urine or bowel, tell the clinician about that uncertainty rather than choosing an explanation yourself.
ACOG describes several possible sources and reasons for abnormal bleeding and how assessment can involve history and examination. Your task is to provide a useful account, not identify the diagnosis. Keep the description with any prior assessment information so that a new clinician can see what changed and avoid relying only on a brief message saying there was some spotting.
Bring every hormone product, including those prescribed elsewhere
Identify estrogen and progesterone or other progestogen products by their full names and forms. Include combination medicines and local vaginal products, not only the most recently started capsule. Tell the clinician about a product change, an interruption or unclear instructions. An accurate account matters more than trying to report the routine you think was expected.
The FDA's hormone categories show why one estrogen name is insufficient to characterize an entire plan. Our systemic-estrogen guide and local-vaginal guide explain the differences. This information can inform assessment, but it does not authorize increasing progesterone, withdrawing another hormone or experimenting with a different pattern to see whether the bleeding stops.
A predicted treatment pattern does not explain every episode
A clinician may discuss bleeding patterns when establishing a hormone regimen. That discussion should identify what was expected in the specific plan and what should trigger contact. It should not become a standing rule that every later episode is normal. ACOG recommends discussing abnormal bleeding changes during the menopause transition as well as bleeding after menopause.
If the pattern differs from what you were told, say so explicitly. A website cannot decide whether an episode fits the original explanation or whether the clinical situation has changed. The current Prometrium record lists abnormal genital bleeding of unknown cause as a contraindication. A new prescription or renewal should not be used to bypass finding out why unexplained bleeding is occurring.
Know what an assessment might involve without selecting a test yourself
The clinician may review the history, examine the relevant tissues and consider imaging or sampling when appropriate. ACOG's patient guidance explains ultrasound, assessment of the uterine lining and other procedures that may be used to investigate bleeding. Their role depends on the clinical question; a symptom description alone does not identify one necessary test for everyone.
Ask what each proposed investigation is intended to find out and who will explain its result. If you had a hysterectomy or another uterine procedure, make that part of the history rather than assuming the usual evaluation applies unchanged. Our hysterectomy questions help clarify the operation. Surgery changes the anatomy that needs consideration, but it is not a reason to dismiss new unexplained bleeding.
Keep routine surveillance separate from responding to symptoms
Some readers encounter guidance that routine endometrial surveillance is unnecessary solely because of low-dose local vaginal estrogen use. The 2025 AUA/SUFU/AUGS guideline makes that limited recommendation. It does not say that bleeding, pain or another new clinical concern should be ignored. Screening someone without a relevant symptom and investigating someone who has one are different tasks.
Likewise, a previously reassuring assessment does not answer every later change. Tell the clinician if bleeding returns, persists or differs from the pattern already evaluated, and ask what follow-up is now needed. This guide supplies no waiting threshold or reassurance based on duration. It also does not replace the clinician's instructions about when to seek urgent help or how to continue prescribed treatment during assessment.
Confirm who will complete the follow-up, not just receive the message
Ask which clinician will assess the bleeding, whether an in-person service is needed and how the findings will reach anyone else managing the hormone prescriptions. If a telehealth service cannot provide a required examination or procedure, there should be a clear handoff rather than an unanswered message. Our care comparison and CoreAge review distinguish published service claims from verified clinical performance.
CoreAge receives first commercial placement because The Uterus Question is part of its promotional publishing network. That relationship cannot diagnose a symptom, guarantee an appropriate response or turn a medicine purchase into an assessment. A completed response includes an explained next step and a known professional responsible for reviewing the outcome.
Sources behind this article
Use the original documents to check their scope. A provider’s offer and a named medicine’s label establish different facts.
- ACOG: Perimenopausal Bleeding and Bleeding After MenopauseMedical society patient guidance · Checked 2026-09-27
- ACOG: Abnormal Uterine BleedingSpecialty society patient guidance; reviewed August 2025 · Checked 2026-09-27
- FDA: current hormone therapy categories and warning changesFederal regulator patient information · Checked 2026-09-27
- DailyMed: current Acertis Prometrium progesterone capsule record, updated July 23, 2026Exact prescription product labeling · Checked 2026-09-27
- AUA/SUFU/AUGS: Genitourinary Syndrome of Menopause Guideline, 2025Multisociety clinical guideline · Checked 2026-09-27